查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193092

痴呆症治疗市场：按适应症、药物类别和分销渠道分类：全球机会分析和行业预测，2021-2031 年

Dementia Drugs Market By Indication, By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 265 Pages | 商品交期: 2-3个工作天内

价格

预计 2021 年全球痴呆症治疗市场将达到 86.6217 亿美元，2022 年至 2031 年的复合年增长率为 8.5%，2031 年将达到 197.427 亿美元。预测。

痴呆症是一种综合症，其特征是思考、行动、记忆和进行日常生活活动的能力下降。 最常见的痴呆症形式是阿尔茨海默病。 痴呆症是由许多主要或次要影响大脑的伤害和疾病引起的。 对痴呆症的认识低下，因此检查和护理受到阻碍的情况很多。 胆碱酯□抑製剂是最常用的处方药，其作用是阻止大脑分解乙□胆碱，而乙□胆碱对学习、记忆和情绪波动至关重要。

由于阿尔茨海默病患病率的增加、药物研发活动的进展以及早期诊断的普及，预计在预测期内，痴呆症药物市场将显着增长。 还有人口老龄化加剧、研发投入增加、强大管线候选药物的存在、医疗基础设施支出增加、发展中地区公众疾病预防意识增强、个人对化疗治疗的需求上升等因素进一步推动了市场的增长。 然而，与产品审批相关的严格政府法规以及与研发活动相关的高成本预计会阻碍市场增长。 另一方面，药物发现技术的加速技术进步和政府对药物开发的高投资是为该行业开闢新途径的因素，并有望为痴呆症药物市场带来重大增长机会。

痴呆症治疗市场根据适应症、药物类别、分销渠道和地区进行细分。 按适应症分为路易体痴呆、帕金森病痴呆、阿尔茨海默病、血管性痴呆等适应症。按药物类别，路易体痴呆、帕金森病痴呆分为阿尔茨海默病痴呆、血管性痴呆等适应症。 按药物类别，市场分为胆碱酯□抑製剂和 NMDA 拮抗剂及其组合。 按分销渠道分为医院药店、零售药店和网上药店。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章痴呆症药物市场：按适应症分类

  • 概览
    • 市场规模和预测
  • 路易体痴呆症
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 帕金森型痴呆
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 阿尔茨海默氏痴呆症
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 血管性痴呆
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他适应症
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章痴呆症药物市场：按治疗类别分类

  • 概览
    • 市场规模和预测
  • 胆碱酯□抑製剂
    • 主要市场趋势、增长因素和机遇
    • 各地区的市场规模和预测
    • 市场份额分析：按国家/地区分类
  • NMDA 拮抗剂及其伴随药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章痴呆症药物市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 零售药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 在线药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章。痴呆症药物市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按适应症分类
    • 北美市场规模和预测：按药物类别
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按适应症分类
    • 欧洲市场规模和预测：按药物类别
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机会
    • 亚太地区的市场规模和预测：按适应症分类
    • 按药物类别划分的亚太市场规模和预测
    • 亚太市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳大利亚
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按适应症分类
    • LAMEA 市场规模和预测：按药物类别
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • apotex inc.
  • Aurobindo Pharma Ltd
  • Biogen Idec
  • Eisai
  • Eli Lilly and Company
  • Johnson & Johnson
  • Abbvie Inc
  • F. Hoffmann-La Roche AG
  • Teva Pharmaceutical Industries
  • Novartis AG
Product Code: A12014

The global dementia drugs market accounted for $8662.17 million in 2021, and is expected to reach $19704.27 million by 2031, registering a CAGR of 8.5% from 2022 to 2031.

Dementia is a syndrome in which there is deterioration in thinking, behavior, memory, and ability to perform daily activities. The most common form of dementia is Alzheimer disease. Dementia results from many injuries and disease that primarily or secondarily impact the brain. There is often lack of awareness about dementia, which results in obstacles to examination and care. Cholinesterase Inhibitors are most commonly prescribed medicines, which help prevent break down of acetylcholine in the brain as acetylcholine is essential in learning, memory, and mood of individual.

It is estimated that the dementia drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Alzheimer's disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, the growing geriatric population, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine, further facilitate the growth of the market. However, strict government regulation related to product approval and high cost linked to R&D activity are expected to impede the market growth. In contrast, accelerated technological advancement in drug discovery technique and high investment by the government for drug development are factors that present new pathway in the industry, which are anticipated to provide significant growth opportunities for the dementia drugs market.

The dementia drugs market is segmented on the basis of indication, drug class, distribution channel, and region. On the basis of indication, the market is bifurcated into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and other indications. Depending on drug class, the market is classified into cholinesterase inhibitors and NMDA antagonist and its combination drugs. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global dementia dugs market. The key companies profiled in the report include AbbVie Inc., APPOTEX Inc., Aurobindo Pharma Limited, Biogen Idec Inc., EISAI GLOBAL, Eli Lilly and company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG and Teva Pharmaceuticals

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dementia drugs market analysis from 2021 to 2031 to identify the prevailing dementia drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the dementia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global dementia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

  • Lewy Body Dementia
  • Parkinsons Disease Dementia
  • Alzheimers Disease
  • Vascular Dementia
  • Other Indications

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Antagonists and its Combination Drugs

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • apotex inc.
    • Aurobindo Pharma Ltd
    • Biogen Idec
    • Eisai
    • Eli Lilly and Company
    • Johnson & Johnson
    • Abbvie Inc
    • , F. Hoffmann-La Roche AG
    • Teva Pharmaceutical Industries
    • Novartis AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Lewy Body Dementia
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Parkinsons Disease Dementia
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Alzheimers Disease
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Vascular Dementia
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country
  • 4.6 Other Indications
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market share analysis by country

CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Cholinesterase Inhibitors
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 NMDA Antagonists and its Combination Drugs
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Retail Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Hospital Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Indication
    • 7.2.3 North America Market size and forecast, by Drug Class
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Indication
      • 7.2.5.1.3 Market size and forecast, by Drug Class
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Indication
      • 7.2.5.2.3 Market size and forecast, by Drug Class
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Indication
      • 7.2.5.3.3 Market size and forecast, by Drug Class
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Indication
    • 7.3.3 Europe Market size and forecast, by Drug Class
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Indication
      • 7.3.5.1.3 Market size and forecast, by Drug Class
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Indication
      • 7.3.5.2.3 Market size and forecast, by Drug Class
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Indication
      • 7.3.5.3.3 Market size and forecast, by Drug Class
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Indication
      • 7.3.5.4.3 Market size and forecast, by Drug Class
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Indication
      • 7.3.5.5.3 Market size and forecast, by Drug Class
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Indication
      • 7.3.5.6.3 Market size and forecast, by Drug Class
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Indication
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Class
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Indication
      • 7.4.5.1.3 Market size and forecast, by Drug Class
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Indication
      • 7.4.5.2.3 Market size and forecast, by Drug Class
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Indication
      • 7.4.5.3.3 Market size and forecast, by Drug Class
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Indication
      • 7.4.5.4.3 Market size and forecast, by Drug Class
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 Australia
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Indication
      • 7.4.5.5.3 Market size and forecast, by Drug Class
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Indication
      • 7.4.5.6.3 Market size and forecast, by Drug Class
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Indication
    • 7.5.3 LAMEA Market size and forecast, by Drug Class
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Indication
      • 7.5.5.1.3 Market size and forecast, by Drug Class
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Indication
      • 7.5.5.2.3 Market size and forecast, by Drug Class
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Indication
      • 7.5.5.3.3 Market size and forecast, by Drug Class
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Indication
      • 7.5.5.4.3 Market size and forecast, by Drug Class
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 apotex inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Aurobindo Pharma Ltd
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Biogen Idec
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eisai
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Eli Lilly and Company
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Johnson & Johnson
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Abbvie Inc
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 , F. Hoffmann-La Roche AG
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Teva Pharmaceutical Industries
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Novartis AG
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. DEMENTIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. NORTH AMERICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. NORTH AMERICA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. U.S. DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. U.S. DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. U.S. DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. CANADA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. CANADA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. CANADA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. MEXICO DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. MEXICO DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. MEXICO DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. EUROPE DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. GERMANY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. GERMANY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. GERMANY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. FRANCE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. FRANCE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. FRANCE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. UK DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. UK DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. UK DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ITALY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ITALY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ITALY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SPAIN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SPAIN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. SPAIN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. REST OF EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. CHINA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. CHINA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. CHINA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. JAPAN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. JAPAN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. JAPAN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. INDIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. INDIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. INDIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. SOUTH KOREA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. AUSTRALIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. AUSTRALIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. AUSTRALIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. LAMEA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. BRAZIL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. BRAZIL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. BRAZIL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. REST OF LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98.APOTEX INC.: COMPANY SNAPSHOT
  • TABLE 99.APOTEX INC.: OPERATING SEGMENTS
  • TABLE 100.APOTEX INC.: PRODUCT PORTFOLIO
  • TABLE 101.APOTEX INC.: NET SALES
  • TABLE 102.APOTEX INC.: KEY STRATERGIES
  • TABLE 103.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
  • TABLE 104.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
  • TABLE 105.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
  • TABLE 106.AUROBINDO PHARMA LTD: NET SALES
  • TABLE 107.AUROBINDO PHARMA LTD: KEY STRATERGIES
  • TABLE 108.BIOGEN IDEC: COMPANY SNAPSHOT
  • TABLE 109.BIOGEN IDEC: OPERATING SEGMENTS
  • TABLE 110.BIOGEN IDEC: PRODUCT PORTFOLIO
  • TABLE 111.BIOGEN IDEC: NET SALES
  • TABLE 112.BIOGEN IDEC: KEY STRATERGIES
  • TABLE 113.EISAI: COMPANY SNAPSHOT
  • TABLE 114.EISAI: OPERATING SEGMENTS
  • TABLE 115.EISAI: PRODUCT PORTFOLIO
  • TABLE 116.EISAI: NET SALES
  • TABLE 117.EISAI: KEY STRATERGIES
  • TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 121.ELI LILLY AND COMPANY: NET SALES
  • TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 123.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 124.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 125.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 126.JOHNSON & JOHNSON: NET SALES
  • TABLE 127.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 128.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 129.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 130.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 131.ABBVIE INC: NET SALES
  • TABLE 132.ABBVIE INC: KEY STRATERGIES
  • TABLE 133., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 134., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 135., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 136., F. HOFFMANN-LA ROCHE AG: NET SALES
  • TABLE 137., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
  • TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
  • TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
  • TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
  • TABLE 141.TEVA PHARMACEUTICAL INDUSTRIES: NET SALES
  • TABLE 142.TEVA PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
  • TABLE 143.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 144.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 146.NOVARTIS AG: NET SALES
  • TABLE 147.NOVARTIS AG: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DEMENTIA DRUGS MARKET SEGMENTATION
  • FIGURE 2.DEMENTIA DRUGS MARKET,2021-2031
  • FIGURE 3.DEMENTIA DRUGS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DEMENTIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DEMENTIA DRUGS MARKET,BY INDICATION,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LEWY BODY DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PARKINSONS DISEASE DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ALZHEIMERS DISEASE DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF VASCULAR DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 18.DEMENTIA DRUGS MARKET,BY DRUG CLASS,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHOLINESTERASE INHIBITORS DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NMDA ANTAGONISTS AND ITS COMBINATION DRUGS DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 21.DEMENTIA DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
  • FIGURE 25.DEMENTIA DRUGS MARKET BY REGION,2021
  • FIGURE 26.U.S. DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 30.FRANCE DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 31.UK DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 41.BRAZIL DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 43.SOUTH AFRICA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF LAMEA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49.COMPETITIVE DASHBOARD
  • FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 51.APOTEX INC..: NET SALES ($MILLION)
  • FIGURE 52.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)
  • FIGURE 53.BIOGEN IDEC.: NET SALES ($MILLION)
  • FIGURE 54.EISAI.: NET SALES ($MILLION)
  • FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
  • FIGURE 56.JOHNSON & JOHNSON.: NET SALES ($MILLION)
  • FIGURE 57.ABBVIE INC.: NET SALES ($MILLION)
  • FIGURE 58., F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)
  • FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES.: NET SALES ($MILLION)
  • FIGURE 60.NOVARTIS AG.: NET SALES ($MILLION)